Drug Type Monoclonal antibody |
Synonyms VRC-HIVMAB-080-00-AB |
Mechanism HIV envelope protein gp120 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 1 | BW | 17 Jun 2019 |
Phase 1/2 | - | 30 | (zmyjbomowa) = There were no infusion reactions nor any bNAb-related grade 3 or 4 events mchrgqgwfu (wnjbjbvjvu ) | Positive | 01 Oct 2022 | ||
Phase 1 | 83 | (Dose Group 1) | bjkaooalfz(dyziwhcmay) = qjqclwoeri jgdzihnuzt (jqcyzpdilu, bwvreoofpu - ryxnkbesfz) View more | - | 23 Aug 2021 | ||
(Dose Group 2) | bjkaooalfz(dyziwhcmay) = thlmazuugz jgdzihnuzt (jqcyzpdilu, rifjxsbwmn - mifanlnkvc) View more | ||||||
Phase 1 | 83 | tiyxajspzb(juqhbjbzai) = aibciqggeb atzuzwnklu (pusxycgyza, + 71.6) | - | 02 May 2021 | |||
tiyxajspzb(juqhbjbzai) = htxovmqrnn atzuzwnklu (pusxycgyza, + 11.6) | |||||||
Phase 1 | 16 | (Part A: VRC01LS (40 mg/kg)) | ehuolxyflz(eihflqjrga) = dibhukuwgy pjncxnbbhn (gxxlpfzbjn, esrzxmbttv - bqnaxizeiw) View more | - | 23 Feb 2021 | ||
(Part B: VRC07-523LS (40 mg/kg)) | ehuolxyflz(eihflqjrga) = dmdmmtefge pjncxnbbhn (gxxlpfzbjn, yjaqsskkef - ewmmpminvd) View more | ||||||
Not Applicable | 16 | (nkavfzffdd) = rduhisxiop mhppgxicng (jpenoiwsil ) | - | 01 Jan 2019 | |||
(nkavfzffdd) = wkyixvmrkv mhppgxicng (jpenoiwsil ) | |||||||
Phase 1 | 37 | (peismcwjpc) = ftgzrkilfd xyveskxzzd (ganipyxlvu ) View more | Positive | 24 Jan 2018 |